The plants to be relocated include a formulation facility in Longquan, Chengdu and a pre-extraction plant which is currently is in the center of Chengdu.
The company said it is investing $25m into the modern plant for expanding capacity, which is scheduled to go on stream early in 2013.
In addition to capacity expansion, the new facility will allow the company to meet new GMP requirements, according to fiercepharmamanufacturing.com.
If demand calls for more products, the company may invest another $10m in the facility in a second phase.